- Home
- SAFE vs DAWN Comparison
SAFE vs DAWN Comparison
Compare SAFE & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFE
- DAWN
- Stock Information
- Founded
- SAFE 2016
- DAWN 2018
- Country
- SAFE United States
- DAWN United States
- Employees
- SAFE N/A
- DAWN N/A
- Industry
- SAFE Real Estate Investment Trusts
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- SAFE Real Estate
- DAWN Health Care
- Exchange
- SAFE Nasdaq
- DAWN Nasdaq
- Market Cap
- SAFE 1.4B
- DAWN 1.6B
- IPO Year
- SAFE 2017
- DAWN 2021
- Fundamental
- Price
- SAFE $20.22
- DAWN $13.31
- Analyst Decision
- SAFE Buy
- DAWN Strong Buy
- Analyst Count
- SAFE 9
- DAWN 7
- Target Price
- SAFE $28.44
- DAWN $36.17
- AVG Volume (30 Days)
- SAFE 397.1K
- DAWN 1.3M
- Earning Date
- SAFE 10-28-2024
- DAWN 10-30-2024
- Dividend Yield
- SAFE 3.50%
- DAWN N/A
- EPS Growth
- SAFE N/A
- DAWN N/A
- EPS
- SAFE 1.70
- DAWN N/A
- Revenue
- SAFE $401,069,000.00
- DAWN $101,953,000.00
- Revenue This Year
- SAFE N/A
- DAWN N/A
- Revenue Next Year
- SAFE $6.18
- DAWN $44.21
- P/E Ratio
- SAFE $11.93
- DAWN N/A
- Revenue Growth
- SAFE 23.33
- DAWN N/A
- 52 Week Low
- SAFE $17.91
- DAWN $11.30
- 52 Week High
- SAFE $28.80
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- SAFE 29.26
- DAWN 35.44
- Support Level
- SAFE $20.09
- DAWN $14.30
- Resistance Level
- SAFE $21.58
- DAWN $15.92
- Average True Range (ATR)
- SAFE 0.75
- DAWN 0.90
- MACD
- SAFE -0.04
- DAWN -0.17
- Stochastic Oscillator
- SAFE 5.40
- DAWN 0.29
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that is net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.